HWAM
BCRX icon

Hennion & Walsh Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$954K Buy
114,525
+1,632
+1% +$15.4K 0.03% 578
2026
Q2 		$1.13M Sell
112,893
-988
-0.9% -$8.93K 0.03% 529
2026
Q1 		$1.08M Buy
113,881
+1,342
+1% +$10.4K 0.04% 494
2025
Q4 		$878K Buy
112,539
+26,794
+31% +$194K 0.03% 556
2025
Q3 		$651K Buy
85,745
+35,290
+70% +$294K 0.02% 635
2025
Q2 		$452K Buy
+50,455
New +$470K 0.02% 701

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
RF
RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Hennion & Walsh Asset Management's BCRX Position: Q3 2026 in Review

Hennion & Walsh Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 1.4% in Q3 2026, buying an estimated $15.4K and bringing the position to 114,525 shares worth $954K. The position accounts for 0.03% of the portfolio, ranked #578.

Hennion & Walsh Asset Management first reported a position in BCRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.13M in Q2 2026. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Hennion & Walsh Asset Management held 114,525 shares of BioCryst Pharmaceuticals worth $954K as of Q3 2026.
  • Hennion & Walsh Asset Management bought 1,632 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $15.4K.
  • BioCryst Pharmaceuticals made up 0.03% of Hennion & Walsh Asset Management's portfolio in Q3 2026, its #578 holding.
  • Hennion & Walsh Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Hennion & Walsh Asset Management's BioCryst Pharmaceuticals position peaked at $1.13M in Q2 2026.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.